TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05395728

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deflate the tracheostomy cuff early
Description: The tracheostomy cuff will be early deflated, on beginning the weaning mechanical ventilation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deflate the tracheostomy cuff after complete weaning mechanical ventilation
Description: The tracheostomy cuff will be deflated onl twenty four hours after complete weaning mechanical ventilation
Study: NCT03743298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-MEL-1
Description: AV-MEL-1: Autologous dendritic cells loaded with autologous tumor antigens (ATA) from a short-term cell culture of autologous tumor cells. AV-MEL-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
Study: NCT05354869

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Urostym
Description: electric pelvic floor muscle stimulator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Urostym
Description: electric pelvic floor muscle stimulator

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: patient education on home exercises and stretching
Study: NCT05570357

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Berberine+Cinnamon (TDS)
Description: The supplements contains 400 mg Berberine, and 200 mg Cinnamon extract

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (TDS)
Description: Placebo contains Maltodexterin
Study: NCT05179057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posoleucel
Description: Administered as 2-4 milliliter infusion, visually identical to placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as 2-4 milliliter infusion, visually identical to Posoleucel
Study: NCT05839067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care-HF
Description: Participants will be trained to use a 5-step problem-solving process based on the Theory of Social Problem-Solving (TSPS) to manage HF-related problems over 12-weeks. The core belief of TSPS is effective problem-solving requires a positive problem orientation (i.e., viewing problems as a challenge versus a threat) and elicits rational problem-solving versus avoidance or impulsivity/carelessness. Problem-solving follows from a positive problem orientation and involves accurate problem identification, generation of appropriate potential solutions, active decision-making, and solution implementation and evaluation. The goal of this intervention is to move participants toward a positive problem orientation and use of rational problem-solving strategies that support greater physical and mental health.
Study: NCT04899011

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire about taste and salivary disturbance before surgery, 10 days, 4 months and 1 year after surgery.~Questionnaires include characteristics of taste disturbance, and specific impact on quality of life.
Study: NCT04944927

Intervention type: OTHER
Intervention: Recording of clinical parameters and electrocardiogram parameters
Description: Retrospective recording of demographic information (age, sex, age at diagnosis), genetic information, cardiological information, pharmacological treatments, electrocardiogram data. All above data will be deidentified.
Study: NCT06020768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the bed-head was raised to an angle of 0, 20, 30 and 45 degrees
Description: With each patient in the supine position, the bed-head was raised to an angle of 0, 20, 30 and 45 degrees without a pillow, and the haemodynamic parameters of central venous pressure, systolic and diastolic blood pressure, heart rate, breathing rate and peripheral oxygen saturation were recorded after 0 and 10 minutes.
Study: NCT04743739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 1000mg, I.V. on Days 1 and 181, and will be retreated or not at Days 15 and 195 according to the CD19+ B cell count.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab 1000mg, I.V. on Days 1 and 181, and will be retreated or not at Days 15 and 195 according to the CD19+ B cell count.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: cyclosporine (CsA) will be started at a dose of 3mg/kg/d and adjusted according to the blood levels of the CsA. CsA will be tapered after 6 months and discontinued over a three month period.
Study: NCT05855213

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Velocity Nasal Insufflation
Description: A relatively new respiratory support modality which delivers very high velocity flows. This improves ventilatory efficiency via washing out carbon dioxide occupying the anatomical dead space of the upper airways.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive positive pressure ventilation
Description: An established non-invasive ventilation method via delivery of an expiratory positive airway pressure and inspiratory positive airway pressure.
Study: NCT05375825

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery
Description: Cytoreductive surgery: minimally invasive (VATS/robotic) or open (thoracotomy)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery
Description: Cytoreductive surgery: minimally invasive (VATS/robotic) or open (thoracotomy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMB-100
Description: 1000 mcg/mL (DL1) post-operative dose as a single 90-minute normothermic intrathoracic perfusion using a closed circuit and roller pump with a heat exchanger following maximal cytoreductive surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMB-100
Description: 1000 mcg/mL (DL1) post-operative dose as a single 90-minute normothermic intrathoracic perfusion using a closed circuit and roller pump with a heat exchanger following maximal cytoreductive surgery

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Immunohistochemical Assay for Mesothelin
Description: Performed at screening to determine mesothelin expression; separate testing of tumor mesothelin expression will be assessed retrospectively in resected tumor tissues. The device is not diagnostic; protocol assessment of mesothelin expression status will only be used to help to increase the possibility that all persons enrolling on the study might derive benefit from therapy.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Immunohistochemical Assay for Mesothelin
Description: Performed at screening to determine mesothelin expression; separate testing of tumor mesothelin expression will be assessed retrospectively in resected tumor tissues. The device is not diagnostic; protocol assessment of mesothelin expression status will only be used to help to increase the possibility that all persons enrolling on the study might derive benefit from therapy.
Study: NCT05589766

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside
Description: Nicotinamide Riboside supplementation up to 3000mg daily in total.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside
Description: Nicotinamide Riboside supplementation up to 3000mg daily in total.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet identical in taste, form and appearance to NR tablets, administered twice daily for a total of 12 weeks.
Study: NCT05085327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChapStick Lip Moisturizer Original
Description: Sunscreen lip balm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChapStick Lip Moisturizer Mint
Description: Sunscreen lip balm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChapStick Lip Moisturizer Black Cherry
Description: Sunscreen lip balm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPF Standard Sunscreen
Description: SPF Standard (7 percent \[%\] Padimate-O and 3% Oxybenzone)
Study: NCT05305625

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: remote ischemic postcondioning
Description: remote ischemic postcondioning twice daily, for three consecutive days，the upper arm of the lighter paralyzed side was pressurized to 200mmHg, pressurized 5min and relaxed for 5 minutes for 4 cycles as a complete remote ischemic postcondioning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard therapy
Description: received standardized treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard therapy
Description: received standardized treatment
Study: NCT05939193

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urine-guided hydration
Description: The target is to maintain urine output at 200 ml/h (3 ml/kg/h) or higher by intravenous injection/infusion of furosemide throughout surgery. That is, a loading dose of 20 mg is injected at the beginning of surgery; if urine output does not reach the target value, furosemide will be continuously infused at 10 mg/h until the end of surgery, with a cumulative dose not exceeding 250 mg. Intravenous rehydration is performed to balance urine output and to maintain the SVV ≤10%.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine hydration
Description: The target is to maintain urine output at 0.5 ml/kg/h or higher according to routine practice. That is, furosemide is only administered when clinically necessary or at discretion of responsible anesthesiologists; intravenous rehydration is performed to maintain the SVV ≤10%.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Forced administration of furosemide
Description: Forced administration of furosemide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine administration of furosemide
Description: Routine administration of furosemide
Study: NCT06389539

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SBD111 medical food
Description: SBD111 medical food is a defined microbial assemblage (DMA) consisting of oligofructose and dried berry powder (prebiotics), a Pseudomonas fluorescens, a Lactobacillus brevis, a Leuconostoc mesenteroides, a Lactobacillus plantarum, and a Pichia kudriavzevii (yeast).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06211972

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OpiVenture
Description: OpiVenture, a targeted psychosocial intervention, complements opioid agonist therapy for opioid use disorder. Adapted from proven interventions like PreVenture, it unfolds over three sessions. Session one covers introductions, an ice-breaker, trait overview, strengths/limitations discussion, goal setting, and homework. Session two reviews homework, explores coping strategies, weighs alternatives, introduces hot thoughts, reviews trait-specific hot thoughts, and assigns homework. The concluding session involves reviewing homework, identifying personal hot thoughts, challenging them through a cognitive-behavioral exercise, applying insights to goal setting, and concluding with a wrap-up.
Study: NCT06100185

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PeakSleep
Description: The PeakSleepTM is a constant current device which delivers stable stimulation as a function of the impedance measured across the electrodes (e.g. it varies voltage to produce a steady current). The device gradually ramps up the current as the impedance decreases during the stimulation session. The device uses stimulation amplitudes in the range of 100uA to 500uA at each electrode pair. Devices will be configured to deliver 100 stimulation trains over 30 minutes where each train is 6 pulses of 0.75Hz trapezoidal stimulation (each train lasts 8 seconds). The inter-train interval is 10 seconds leading to a total stimulation time of \<14 minutes with a maximum dose of 1mA (500uA per electrode pair).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham is delivered with the same devices which are alternatively configured to deliver a trivially low amplitude (e.g. 100uA) waveform of a different frequency (e.g. 25 Hz) for the same treatment duration. Beyond differences in amplitude and frequency of stimulation, devices will be operated in exactly the same way during sham treatment.
Study: NCT05068102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765063
Description: BI 765063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezabenlimab
Description: Ezabenlimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezabenlimab
Description: Ezabenlimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [89Zr]Zr- BI 765063
Description: \[89Zr\]Zr- BI 765063, specifically radiolabelled for immune-Positron Emission Tomography (PET)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 770371
Description: BI 770371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [89Zr]Zr- BI 770371
Description: \[89Zr\]Zr- BI 770371, specifically radiolabelled for immune-PET
Study: NCT05728684

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM310
Description: CM310 Injection
Study: NCT05981352

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mineral trioxide aggregate pulpotomy
Description: * After achieving hemostats, Mineral trioxide aggregate powder will be mixed with saline.~* Then Mineral trioxide aggregate will be placed directly on the pulp stumps.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dehydrated amniotic membrane pulpotomy
Description: * After achieving haemostasis, a double layer of sterile processed human allograft tis¬sue (dehydrated dual-layer dental amni¬on patch) will be trimed and soaked in saline for a minute.~* Dehydrated amniotic membrane will be Placed directly on the pup stumps using sterile tweezers and adjust¬ed to the entire floor of the pulp chamber.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid pulpotomy
Description: * After achieving haemostasis, pulp stumps will be covered with a mixture of Hyaluronic acid gel and zinc oxide powder with consistency (1:1 ratio by volume) .~* The cavities of all pulpotomy molars will be sealed with a layer of reinforced zinc oxide and eugenol .
Study: NCT04973163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1823911
Description: BI 1823911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1823911
Description: BI 1823911
Study: NCT05608200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib, sintilimab plus TACE
Description: Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd and sintilimab (200mg I.V. q3w) will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated. Treatment of sintilimab will last up to 24 months. Patients will be allowed to have lenvatilib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib plus TACE
Description: Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated. The interruption, dose reduction and discontinuation of lenvatinib depended on the presence and severity of toxicities according to the drug directions.
Study: NCT04973163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1701963
Description: BI 1701963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam - only administered in Part B (dose confirmation) of the Monotherapy Arm
Study: NCT05791162

Intervention type: OTHER
Group type: OTHER
Intervention: Blood collection
Description: Collection of 3 blood tubes at inclusion and relapse (arm 1) or at inclusion, initiation of treatment and at 3 and 6 months post-diagnosis (arm 2)

Intervention type: OTHER
Group type: OTHER
Intervention: Blood collection
Description: Collection of 3 blood tubes at inclusion and relapse (arm 1) or at inclusion, initiation of treatment and at 3 and 6 months post-diagnosis (arm 2)

Intervention type: OTHER
Group type: OTHER
Intervention: Urine sample
Description: Collection of 20 cc of urine at inclusion and relapse (arm 1) or at inclusion, initiation of treatment and at 3 and 6 months post-diagnosis (arm 2) or at inclusion only (arm 3)

Intervention type: OTHER
Group type: OTHER
Intervention: Urine sample
Description: Collection of 20 cc of urine at inclusion and relapse (arm 1) or at inclusion, initiation of treatment and at 3 and 6 months post-diagnosis (arm 2) or at inclusion only (arm 3)

Intervention type: OTHER
Group type: OTHER
Intervention: Urine sample
Description: Collection of 20 cc of urine at inclusion and relapse (arm 1) or at inclusion, initiation of treatment and at 3 and 6 months post-diagnosis (arm 2) or at inclusion only (arm 3)
Study: NCT06638099

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CGM Toolkit Prescriber Training
Description: A CGM prescription toolkit was created for prescribing clinicians and staff that includes written guidance on CGM eligibility criteria, instructions for screening patients for eligibility using EHR records and during healthcare visits, recommended provider documentation templates to address all required eligibility criteria for insurance coverage of CGM device and supplies (e.g., Medicare, Medicaid), sample scripts for communicating with patients about the purpose and use of CGM, and patient-level frequently asked questions (FAQs), including free resources available to learn more about CGM benefits, where/how to acquire CGM, and determining out-of-pocket costs. The toolkit will be introduced during a 20 minute initial training session and reinforced during a 10 minute booster training approximately one month after initial training
Study: NCT05829564

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: The individuals participating in the study will experience virtual reality.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical mobilization
Description: The individuals participating in the study will be applied cervical mobilization techniques.

Intervention type: OTHER
Group type: OTHER
Intervention: exercise
Description: The individuals participating in the study will performed neck-specific exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: The individuals participating in the study will performed neck-specific exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: The individuals participating in the study will performed neck-specific exercises.
Study: NCT05956028

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided SCV cannulation
Description: receive ultrasound guided SCV cannulation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided SCV cannulation
Description: receive ultrasound guided SCV cannulation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided IJV cannulation
Description: receive ultrasound guided IJV cannulation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided IJV cannulation
Description: receive ultrasound guided IJV cannulation
Study: NCT05050383

Intervention type: OTHER
Group type: OTHER
Intervention: Pharyngeal Manometry
Description: Catheters will be passed into the nose and advanced to the pharynx to measure airway pressures during drug-induced sleep.
Study: NCT04658017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GARNET device
Description: Use of new filter in conjunction with standard of care dialysis.
Study: NCT05050383

Intervention type: OTHER
Group type: OTHER
Intervention: Submental Ultrasound
Description: Ultrasound of airway soft tissues
Study: NCT06168981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing Gum
Description: The patient will be asked to chew gum before the surgery during the 2 minutes. Anxiety level will evaluated before and after chewing gum.
Study: NCT06261710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sonography in labour
Description: Using intrapartum sonography parameters in labour
Study: NCT06433713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine IV
Description: They received IV infusion of 2 mg/kg per hour of lidocaine starting with skin incision, which was maintained until skin closure. This was done using a syringe pump with the calculated amount of lidocaine added to 50 ml of normal saline infused at a rate of 50 ml/hr.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% normal saline infusion
Study: NCT04859296

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaporized placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low CBG
Description: Vaporized CBG (5 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low CBG
Description: Vaporized CBG (5 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low CBG
Description: Vaporized CBG (5 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High CBG
Description: Vaporized CBG (15 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High CBG
Description: Vaporized CBG (15 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High CBG
Description: Vaporized CBG (15 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low THC
Description: Vaporized THC (5 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low THC
Description: Vaporized THC (5 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low THC
Description: Vaporized THC (5 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High THC
Description: Vaporized THC (15 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High THC
Description: Vaporized THC (15 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High THC
Description: Vaporized THC (15 mg)
Study: NCT06036212

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic System
Description: Robotic assisted Unicompartmental Knee replacement (UKA)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Conventional
Description: Unicompartmental Knee Arthroplasty (UKA) with conventional approach and conventional manual instrumentation
Study: NCT05661175

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: one-handed technique
Description: Traditional percutaneous nephrolithotripsy usually requires the left hand to hold the nephroscope and the right hand to control the fiber for lithotripsy.Our intervention is to control the depth and direction of the sheath with the left hand, the nephroscope in the right hand and control the fiber optic lithotripsy